EP2621932A4 - Composés hétérocycliques tétracycliques pour le traitement d'une infection par le virus de l'hépatite c - Google Patents

Composés hétérocycliques tétracycliques pour le traitement d'une infection par le virus de l'hépatite c

Info

Publication number
EP2621932A4
EP2621932A4 EP11828123.7A EP11828123A EP2621932A4 EP 2621932 A4 EP2621932 A4 EP 2621932A4 EP 11828123 A EP11828123 A EP 11828123A EP 2621932 A4 EP2621932 A4 EP 2621932A4
Authority
EP
European Patent Office
Prior art keywords
hepatitis
treatment
virus infection
heterocyclic compounds
tetracyclic heterocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11828123.7A
Other languages
German (de)
English (en)
Other versions
EP2621932A1 (fr
Inventor
Michael P Dwyer
Kartik M Keertikar
Craig A Coburn
Hao Wu
Bin Hu
Bin Zhong
Chengren Zhang
Zhigang Dan
Ling Tong
Wensheng Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2010/077498 external-priority patent/WO2012040924A1/fr
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of EP2621932A1 publication Critical patent/EP2621932A1/fr
Publication of EP2621932A4 publication Critical patent/EP2621932A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP11828123.7A 2010-09-29 2011-09-28 Composés hétérocycliques tétracycliques pour le traitement d'une infection par le virus de l'hépatite c Withdrawn EP2621932A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2010/077498 WO2012040924A1 (fr) 2010-09-29 2010-09-29 Composés hétérocycliques tétracycliques condensés et leurs méthodes d'utilisation pour le traitement de maladies virales
US201061426738P 2010-12-23 2010-12-23
PCT/CN2011/080270 WO2012041227A1 (fr) 2010-09-29 2011-09-28 Composés hétérocycliques tétracycliques pour le traitement d'une infection par le virus de l'hépatite c

Publications (2)

Publication Number Publication Date
EP2621932A1 EP2621932A1 (fr) 2013-08-07
EP2621932A4 true EP2621932A4 (fr) 2014-03-26

Family

ID=45891961

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11828123.7A Withdrawn EP2621932A4 (fr) 2010-09-29 2011-09-28 Composés hétérocycliques tétracycliques pour le traitement d'une infection par le virus de l'hépatite c

Country Status (2)

Country Link
EP (1) EP2621932A4 (fr)
WO (1) WO2012041227A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA020031B1 (ru) 2009-06-11 2014-08-29 Эббви Бахамаз Лтд. Противовирусные соединения
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
AU2010274001A1 (en) 2009-07-16 2012-02-23 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of Flavivirus infections
CN102869657A (zh) 2010-03-24 2013-01-09 沃泰克斯药物股份有限公司 用于治疗或预防黄病毒感染的类似物
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
US8859595B2 (en) 2010-08-26 2014-10-14 Rfs Pharma, Llc Potent and selective inhibitors of hepatitis C virus
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CA2841095A1 (fr) 2011-07-09 2013-01-17 Sunshine Lake Pharma Co., Ltd. Composes spiro en tant qu'inhibiteurs du virus de l'hepatite c
WO2013030750A1 (fr) 2011-09-01 2013-03-07 Lupin Limited Composés antiviraux
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2013217224B2 (en) 2012-02-10 2017-04-06 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
CN103848818B (zh) 2012-11-29 2017-03-15 广东东阳光药业有限公司 作为丙型肝炎抑制剂的并环化合物、药物组合物及它们在药物中的应用
CN103848821B (zh) 2012-11-29 2016-10-12 广东东阳光药业有限公司 作为丙型肝炎抑制剂的螺环化合物、药物组合物及它们的用途
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
WO2015089810A1 (fr) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Composés tétracycliques hétérocycliques condensés et leurs procédés d'utilisation pour le traitement de maladies virales
WO2015103490A1 (fr) 2014-01-03 2015-07-09 Abbvie, Inc. Formes galéniques antivirales solides
WO2015110048A1 (fr) 2014-01-23 2015-07-30 Sunshine Lake Pharma Co., Ltd. Composés cycliques pontés comme inhibiteurs du virus de l'hépatite c, compositions pharmaceutiques et utilisations correspondantes
KR102430183B1 (ko) 2014-09-26 2022-08-08 더 케무어스 컴퍼니 에프씨, 엘엘씨 아이소시아네이트 유도된 유기실란
CN104478877B (zh) * 2014-10-31 2016-08-24 广东东阳光药业有限公司 制备雷迪帕韦中间体的方法
WO2017023631A1 (fr) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
CA3235146A1 (fr) 2021-10-14 2023-04-20 Incyte Corporation Composes de quinoleine utiles en tant qu'inhibiteurs de kras

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008021928A2 (fr) * 2006-08-11 2008-02-21 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1719773E (pt) * 2004-02-24 2009-06-03 Japan Tobacco Inc Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv
WO2006046039A2 (fr) * 2004-10-26 2006-05-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Derives d'indole tetracycliques utilises comme agents antiviraux
AU2008295483B2 (en) * 2007-08-29 2013-11-21 Merck Sharp & Dohme Corp. Tetracyclic indole derivatives and their use for treating or preventing viral infections

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008021928A2 (fr) * 2006-08-11 2008-02-21 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2012041227A1 *

Also Published As

Publication number Publication date
WO2012041227A1 (fr) 2012-04-05
EP2621932A1 (fr) 2013-08-07

Similar Documents

Publication Publication Date Title
EP2621932A4 (fr) Composés hétérocycliques tétracycliques pour le traitement d'une infection par le virus de l'hépatite c
EP2621931A4 (fr) Dérivés d'indoles tétracycliques pour le traitement d'une infection par le virus de l'hépatite c
EP2744332A4 (fr) Composés benzofuranes pour le traitement d'infections par le virus de l'hépatite c
EP2658857A4 (fr) Nucléosides puriques substitués, dérivés phosphoramidate et phosphorodiamidate pour le traitement d'infections virales
EP2888240A4 (fr) Composés pour le traitement d'infections virales par paramyxovirus
EP2552203A4 (fr) Composés et compositions pharmaceutiques pour le traitement d'infections virales
EP2633051A4 (fr) Traitement d'une infection par le vhb
EP2385951A4 (fr) Dérivés de phosphoramidate de composés guanosine nucléoside pour le traitement d'infections virales
EP2558466A4 (fr) Phosphonates présentant une toxicité réduite pour le traitement d'infections virales
MA37712B1 (fr) Inhibiteurs macrocycliques de virus flaviviridae
EP2516430A4 (fr) Composés tricycliques fusionnés et leurs méthodes d'utilisation pour le traitement de maladies virales
EP2503881A4 (fr) Composés tricycliques fusionnés et leurs dérivés utiles pour le traitement de maladies virales
EP2753618A4 (fr) Dérivés benzofuranes substitués par un hétérocycle et leurs procédés d'utilisation pour le traitement de maladies virales
EP2807252A4 (fr) Méthodes pour augmenter la capacité d'infection des virus
EP2816054A4 (fr) Composés macrocycliques pour supprimer la réplication du virus de l'hépatite c
EP2254582A4 (fr) Méthodes de traitement d'infections virales
EP2632452A4 (fr) Composés et compositions pour le traitement du cancer
EP2753611A4 (fr) Composés benzofuranes substitués et leurs procédés d'utilisation pour le traitement de maladies virales
EP2782578A4 (fr) Méthode pour traiter une infection par le virus de l'hépatite c à l'aide de compositions contenant de la quercétine
EP2646043A4 (fr) Nouveaux dérivés de ciclosporine destinés au traitement et à la prévention d'une infection virale
EP2953456A4 (fr) Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de l'hépatite c
EP2534150A4 (fr) Méthodes de traitement d'une infection virale
EP2296654A4 (fr) Dérivés de 8-hydroxyquinoline pour le traitement d'hémopathies malignes
EP2341924A4 (fr) Méthodes de traitement d une infection par le virus de l hépatite c
EP2709619A4 (fr) Composés utilisés dans le traitement de la mucosite

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130429

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20140224

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/437 20060101ALI20140218BHEP

Ipc: C07D 493/22 20060101ALI20140218BHEP

Ipc: C07D 471/22 20060101ALI20140218BHEP

Ipc: C07D 491/22 20060101ALI20140218BHEP

Ipc: C07D 498/04 20060101AFI20140218BHEP

Ipc: A61K 31/4985 20060101ALI20140218BHEP

Ipc: C07D 471/04 20060101ALI20140218BHEP

Ipc: A61K 31/5365 20060101ALI20140218BHEP

Ipc: C07D 487/04 20060101ALI20140218BHEP

Ipc: A61P 31/14 20060101ALI20140218BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140924